dc.date.accessioned |
2023-03-06T07:33:11Z |
|
dc.date.available |
2023-03-06T07:33:11Z |
|
dc.date.issued |
2022 |
|
dc.identifier.citation |
Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):169-173. doi: 10.1016/j.clml.2021.09.010. Epub 2021 Sep 15. |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/100565 |
|
dc.relation.isversionof |
10.1016/j.clml.2021.09.010 |
|
dc.relation.isversionof |
10.1016/j.clml.2021.09.010 |
|
dc.title |
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL |
|
dc.relation.journal |
Clin Lymphoma Myeloma Leuk |
|
dc.identifier.doi |
10.1016/j.clml.2021.09.010 |
|
dc.contributor.author |
Akpinar S |
|
dc.contributor.author |
Akpinar S |
|
dc.contributor.author |
Dogu MH |
|
dc.contributor.author |
Celik S |
|
dc.contributor.author |
Ekinci O |
|
dc.contributor.author |
Hindilerden IY |
|
dc.contributor.author |
Dal MS |
|
dc.contributor.author |
Davulcu EA |
|